AbCellera Biologics Inc. ABCL Return on equity

Return on equity at other companies

SchrodingerSDGR

-45.7%—

Twist Bioscience CorporationTWST

-18.2%-6.3pp

Recursion Pharmaceuticals, Inc.RXRX

-56.6%-14.5pp

Ginkgo BioworksDNA

-56.3%+23.1pp

Absci CorporationABSI

-63.9%+28.0pp

Avalo TherapeuticsAVTX

-36.3%—

FAQ

What is AbCellera Biologics Inc.'s return on equity?

AbCellera Biologics Inc. (ABCL) reported return on equity of -17.3% in Q2 2026.

How has AbCellera Biologics Inc.'s return on equity changed year-over-year?

AbCellera Biologics Inc.'s return on equity decreased by 10.6% year-over-year, from -15.6% to -17.3%.

What is the long-term trend for AbCellera Biologics Inc.'s return on equity?

Over 4 years (2020 to 2025), AbCellera Biologics Inc.'s return on equity has grown at a -15.4% compound annual growth rate (CAGR), from 28.3% to -14.5%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.